Exploring the frontiers: The potential and challenges of bioactive scaffolds in osteosarcoma treatment and bone regeneration

IF 8.7 1区医学 Q1 ENGINEERING, BIOMEDICAL

Materials Today Bio Pub Date : 2024-09-29 DOI:10.1016/j.mtbio.2024.101276

Huaiyuan Zhang , Yu Wang , Huifen Qiang , Dewen Leng , Luling Yang , Xueneng Hu , Feiyan Chen , Tinglin Zhang , Jie Gao , Zuochong Yu

{"title":"Exploring the frontiers: The potential and challenges of bioactive scaffolds in osteosarcoma treatment and bone regeneration","authors":"Huaiyuan Zhang , Yu Wang , Huifen Qiang , Dewen Leng , Luling Yang , Xueneng Hu , Feiyan Chen , Tinglin Zhang , Jie Gao , Zuochong Yu","doi":"10.1016/j.mtbio.2024.101276","DOIUrl":null,"url":null,"abstract":"<div><div>The standard treatment for osteosarcoma combines surgery with chemotherapy, yet it is fraught with challenges such as postoperative tumor recurrence and chemotherapy-induced side effects. Additionally, bone defects after surgery often surpass the body's regenerative ability, affecting patient recovery. Bioengineering offers a novel approach through the use of bioactive scaffolds crafted from metals, ceramics, and hydrogels for bone defect repair. However, these scaffolds are typically devoid of antitumor properties, necessitating the integration of therapeutic agents. The development of a multifunctional therapeutic platform incorporating chemotherapeutic drugs, photothermal agents (PTAs), photosensitizers (PIs), sound sensitizers (SSs), magnetic thermotherapeutic agents (MTAs), and naturally occurring antitumor compounds addresses this limitation. This platform is engineered to target osteosarcoma cells while also facilitating bone tissue repair and regeneration. This review synthesizes recent advancements in integrated bioactive scaffolds (IBSs), underscoring their dual role in combating osteosarcoma and enhancing bone regeneration. We also examine the current limitations of IBSs and propose future research trajectories to overcome these hurdles.</div></div>","PeriodicalId":18310,"journal":{"name":"Materials Today Bio","volume":"29 ","pages":"Article 101276"},"PeriodicalIF":8.7000,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materials Today Bio","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590006424003375","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The standard treatment for osteosarcoma combines surgery with chemotherapy, yet it is fraught with challenges such as postoperative tumor recurrence and chemotherapy-induced side effects. Additionally, bone defects after surgery often surpass the body's regenerative ability, affecting patient recovery. Bioengineering offers a novel approach through the use of bioactive scaffolds crafted from metals, ceramics, and hydrogels for bone defect repair. However, these scaffolds are typically devoid of antitumor properties, necessitating the integration of therapeutic agents. The development of a multifunctional therapeutic platform incorporating chemotherapeutic drugs, photothermal agents (PTAs), photosensitizers (PIs), sound sensitizers (SSs), magnetic thermotherapeutic agents (MTAs), and naturally occurring antitumor compounds addresses this limitation. This platform is engineered to target osteosarcoma cells while also facilitating bone tissue repair and regeneration. This review synthesizes recent advancements in integrated bioactive scaffolds (IBSs), underscoring their dual role in combating osteosarcoma and enhancing bone regeneration. We also examine the current limitations of IBSs and propose future research trajectories to overcome these hurdles.

Abstract Image

查看原文本刊更多论文

探索前沿：生物活性支架在骨肉瘤治疗和骨再生中的潜力与挑战

骨肉瘤的标准治疗方法是手术与化疗相结合，但这一方法充满了挑战，如术后肿瘤复发和化疗引起的副作用。此外，手术后的骨缺损往往超过人体的再生能力，影响患者的康复。生物工程提供了一种新方法，即使用金属、陶瓷和水凝胶制成的生物活性支架进行骨缺损修复。然而，这些支架通常不具备抗肿瘤特性，因此需要整合治疗药物。多功能治疗平台的开发解决了这一局限性，该平台融合了化疗药物、光热剂（PTA）、光敏剂（PI）、声敏化剂（SS）、磁性热疗剂（MTA）和天然抗肿瘤化合物。该平台旨在靶向骨肉瘤细胞，同时促进骨组织的修复和再生。本文综述了集成生物活性支架（IBS）的最新进展，强调了其在抗击骨肉瘤和促进骨再生方面的双重作用。我们还探讨了集成生物活性支架目前存在的局限性，并提出了克服这些障碍的未来研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Materials Today Bio Multiple-

CiteScore

8.30

自引率

4.90%

发文量

303

审稿时长

30 days

期刊介绍： Materials Today Bio is a multidisciplinary journal that specializes in the intersection between biology and materials science, chemistry, physics, engineering, and medicine. It covers various aspects such as the design and assembly of new structures, their interaction with biological systems, functionalization, bioimaging, therapies, and diagnostics in healthcare. The journal aims to showcase the most significant advancements and discoveries in this field. As part of the Materials Today family, Materials Today Bio provides rigorous peer review, quick decision-making, and high visibility for authors. It is indexed in Scopus, PubMed Central, Emerging Sources, Citation Index (ESCI), and Directory of Open Access Journals (DOAJ).